CLGN - CONSENSUS CO - CollPlant Biotechnologies

Stable biomaterial supply chains ensure uninterrupted medical supplies, while ownership of rhCollagen patents grants CollPlant (CLGN) full pricing power. This price chart reflects a market trend for the asset with a value of 120.36. The business relies on the production of recombinant proteins for aesthetics and 3D bioprinting, delivering innovative solutions to clinics and the pharma sector for tissue regeneration.

This indicator measures the gap between the current price and the average expert target price, allowing for an assessment of the asset's margin of safety through the lens of expected returns. The history of the consensus target price for CollPlant (CLGN) reflects market confidence in the commercialization of Vercollagen and the success of clinical trials, where the upside trend serves as an indicator of the capitalization's resilience to biotechnology sector risks.